Day 3 Program

Poster Spotlight 7: Liquid Biopsy in Motion: From Molecular Residual Disease to Treatment Interception

Day 3: December 10, 2026

7:00 AM–8:30 AM CST

302 ABC

Session Details

Moderator

Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium

PS7-1

Global ctDNA kinetics under first-line aromatase inhibitor plus palbociclib: an analysis from PADA-1

François-Clément Bidard, Curie Institute, Paris & Saint-Cloud, France

PS7-2

Impact of timing of ctDNA testing on molecular residual disease detection in early-stage HR+/HER2− Breast Cancer: A DARE Trial Analysis

Lajos Pusztai, Yale School of Medicine, New Haven, CT

PS7-3

Circulating tumor DNA (ctDNA) dynamics during neoadjuvant therapy in early-stage triple-negative breast cancer: preliminary results from the B-STRONGER-I study

Pavani Chalasani, The George Washington Cancer Center, Washington, DC

PS7-5

Circulating tumor DNA dynamics during treatment to predict response and progression in metastatic breast cancer

Andrew A. Davis, Washington University in St. Louis, St. Louis, MO

PS7-6

Molecular surveillance and interception: when should a liquid biopsy change what we do?

Daniel G Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH

PS7-7

Unravelling the genomic evolution of lethal breast cancer using circulating tumour DNA

Nida Pasha, The Institute of Cancer Reasearch, London, United Kingdom

PS7-8

Circulating tumor DNA (ctDNA)-based biomarker analysis of datopotamab deruxtecan (Dato-DXd) versus chemotherapy (CT) in locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC): a prespecified exploratory analysis of TROPION-Breast02

Tiffany A Traina, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY

PS7-9

Longitudinal ctDNA tumor fraction captures disease dynamics and survival risk in the TBCRC/AURORA US prospective biospecimen repository in metastatic breast cancer

Adrian Vincent Lee, University of Pittsburgh, Pittsburgh, PA

PS7-10

Serial circulating tumour DNA monitoring in metastatic breast cancer using an ultrasensitive tumour-informed structural variant based assay

Kareena Thakur, Princess Margaret Cancer Centre, Toronto, ON, Canada

PS7-11

Liquid Biopsy-Based Nucleosome Profiling of Cell-Free DNA (cfDNA) to Predict Estrogen Receptor (ER) Status and Response to Endocrine Therapy (ET)

Stefania Morganti, Dana-Farber Cancer Institute, Boston, MA

PS7-12

Early ctDNA dynamics and its association with patient(pt)-reported outcomes (PRO) in ESR1m emergent HR+/HER2− advanced breast cancer (ABC): exploratory analyses from SERENA-6

Stephen Chia, BC Cancer Agency, Vancouver, BC, Canada

PS7-13

Beyond Detection: liquid biopsy for tumor biology, response, and treatment selection

Michail Ignatiadis, Institut Jules Bordet, Brussels, Belgium